<?xml version="1.0" encoding="UTF-8"?>
<p>Human cytomegalovirus (HCMV) reactivation and HCMV-associated disease are leading reasons for the failure of hematopoietic stem cell transplantations [
 <xref rid="B10-cells-09-00031" ref-type="bibr">10</xref>,
 <xref rid="B11-cells-09-00031" ref-type="bibr">11</xref>,
 <xref rid="B12-cells-09-00031" ref-type="bibr">12</xref>]. Anti-HCMV drugs, including ganciclovir, cidofovir, and foscarnet, are available, but their use is associated with severe side effects [
 <xref rid="B13-cells-09-00031" ref-type="bibr">13</xref>]. In particular, the use of ganciclovir (and its prodrug valganciclovir), the mainstay treatment for cytomegalovirus disease, is associated with severe hematological side effects, including thrombocytopenia [
 <xref rid="B14-cells-09-00031" ref-type="bibr">14</xref>,
 <xref rid="B15-cells-09-00031" ref-type="bibr">15</xref>,
 <xref rid="B16-cells-09-00031" ref-type="bibr">16</xref>].
</p>
